跳至主要内容
临床试验/IRCT20200409047007N2
IRCT20200409047007N2已完成3 期

The effect of methylene blue on acute respiratory distress syndrome in Covid-19 disease

Mashhad University of Medical Sciences0 个研究点目标入组 130 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
130

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • The patient has received remdesivir and corticosteroids and antibiotics and anticoagulants
  • At least one day and at most 5 days have passed since the patient's hospitalization.
  • O2 saturation for 10 minutes without oxygen is less than 89 and more than 75
  • Age between 18 to 75 year
  • Does not have a history of G6PD Deficiency
  • Absence of chronic renal failure with GFR <30
  • Absence of heart failure with EF<40%
  • Does not have COPD with CO2>45
  • The patient is not intubated
  • Does not have systolic Blood Pressure <90
  • Do not take SSRI, MAO Inhibitor drugs
  • Has not received plasma therapy, IVIG, hemoperfusion, Tocilizumab and plasmapheresis before administration of methylene blue
  • Does not be pregnant
  • The patient should be conscious

排除标准

  • Patient dissatisfaction
  • History of allergy or gastrointestinal intolerance to methylene blue

研究者

相似试验